Document Detail

Targeting Individual GPCRs with Redesigned Nonvisual Arrestins.
MedLine Citation:
PMID:  24292829     Owner:  NLM     Status:  In-Data-Review    
Numerous human diseases are caused by excessive signaling of mutant G protein-coupled receptors (GPCRs) or receptors that are overstimulated due to upstream signaling imbalances. The feasibility of functional compensation by arrestins with enhanced ability to quench receptor signaling was recently tested in the visual system. The results showed that even in this extremely demanding situation of rods that have no ability to phosphorylate rhodopsin, enhanced arrestin improved rod morphology, light sensitivity, survival, and accelerated photoresponse recovery. Structurally distinct enhanced mutants of arrestins that bind phosphorylated and non-phosphorylated active GPCRs with much higher affinity than parental wild-type (WT) proteins have been constructed. These "super-arrestins" are likely to have the power to dampen the signaling by hyperactive GPCRs. However, most cells express 5-20 GPCR subtypes, only one of which would be overactive, while nonvisual arrestins are remarkably promiscuous, binding hundreds of different GPCRs. Thus, to be therapeutically useful, enhanced versions of nonvisual arrestins must be made fairly specific for particular receptors. Recent identification of very few arrestin residues as key receptor discriminators paves the way to the construction of receptor subtype-specific nonvisual arrestins.
Luis E Gimenez; Sergey A Vishnivetskiy; Vsevolod V Gurevich
Related Documents :
18623169 - Subtype selective kainic acid receptor agonists: discovery and approaches to rational d...
24753049 - Neurotransmitter signaling in white matter.
1665609 - Excitatory amino acid receptors in the mammalian periphery.
24028379 - Pregnane xenobiotic receptors and membrane progestin receptors: role in neurosteroid-me...
1675289 - Activation of presynaptic 5-hydroxytryptamine1-like receptors on glutamatergic terminal...
21671899 - From in vivo gene targeting of oestrogen receptors to optimization of their modulation ...
15590769 - Inverse agonism and neutral antagonism at wild-type and constitutively active mutant de...
18758759 - Drug discrimination and neurochemical studies in alpha7 null mutant mice: tests for the...
15078139 - Chemokines and their receptors as therapeutic targets: the role of the sdf-1/cxcr4 axis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Handbook of experimental pharmacology     Volume:  219     ISSN:  0171-2004     ISO Abbreviation:  Handb Exp Pharmacol     Publication Date:  2014  
Date Detail:
Created Date:  2013-12-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902231     Medline TA:  Handb Exp Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  153-70     Citation Subset:  IM    
Department of Pharmacology, Vanderbilt University, 2200 Pierce Avenue, Nashville, TN, 37232, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhanced phosphorylation-independent arrestins and gene therapy.
Next Document:  ?-Arrestins and G Protein-Coupled Receptor Trafficking.